Abstract
Access to novel medicines was a disputed issue during the formation of Trade-Related Aspects of Intellectual Property Rights (TRIPs) agreement as developing countries had concerns that the patent rights on pharmaceutical products may produce negative implications on the induction of novel drugs. After a decade of TRIPs agreement, this study aims to evaluate the trends of novel drugs induction in Pakistan. The results of this study indicated a marked and consistent decline in the entries of novel drugs in the post era of TRIPs agreement which indicated that the access to novel medicines issue likely amplified rather improved by giving the incentive of patent rights on the pharmaceutical products. Stakeholders should make cohesive policies to ensure the early induction of novel drugs to make them affordable in Pakistan.